Anmelden

Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.

Although all competitive neuromuscular blockers are designed to produce desirable pharmacological actions, they can also have adverse effects mediated by histamine or autonomic receptors. Drugs like tubocurarine and atracurium lead to histamine release into the systemic circulation. Histamine can cause a fall in blood pressure or hypotension. Pancuronium increases the heart rate and cardiac output. The release of larger doses of histamine can block autonomic ganglions, which affects cardiovascular functions, increasing the heart rate and blood pressure. Bradycardia occurs initially, followed by tachycardia. Prolonged administration of drugs like succinylcholine can result in cardiac arrhythmias and even cardiac arrest in some patients. Other patients may experience flushing, bronchospasm, and increased respiratory secretions.

Tags

Nondepolarizing Neuromuscular BlockersPharmacological ActionsMuscle Contraction InhibitionHistamine ReleaseCompetitive Neuromuscular BlockersAdverse EffectsTubocurarineAtracuriumHypotensionPancuroniumCardiac OutputBradycardiaTachycardiaSuccinylcholineCardiac Arrhythmias

Aus Kapitel 7:

article

Now Playing

7.4 : Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

Skeletal Muscle Relaxants

342 Ansichten

article

7.1 : Neuromuskuläre Verbindung und Blockade

Skeletal Muscle Relaxants

2.6K Ansichten

article

7.2 : Klassifizierung von Skelettmuskelrelaxantien

Skeletal Muscle Relaxants

2.3K Ansichten

article

7.3 : Nichtdepolarisierende (kompetitive) neuromuskuläre Blocker: Wirkmechanismus

Skeletal Muscle Relaxants

1.2K Ansichten

article

7.5 : Nichtdepolarisierende (kompetitive) neuromuskuläre Blocker: Pharmakokinetik

Skeletal Muscle Relaxants

404 Ansichten

article

7.6 : Depolarisierende Blocker: Wirkmechanismus

Skeletal Muscle Relaxants

1.0K Ansichten

article

7.7 : Depolarisierende Blocker: Pharmakokinetik

Skeletal Muscle Relaxants

277 Ansichten

article

7.8 : Direkt wirkende Muskelrelaxanzien: Dantrolen und Botulinumtoxin

Skeletal Muscle Relaxants

596 Ansichten

article

7.9 : Skelettmuskelrelaxanzien: Nebenwirkungen

Skeletal Muscle Relaxants

306 Ansichten

article

7.10 : Skelettmuskelrelaxanzien: Therapeutische Anwendungen

Skeletal Muscle Relaxants

432 Ansichten

article

7.11 : Spasmolytische Mittel: Chemische Klassifizierung

Skeletal Muscle Relaxants

828 Ansichten

article

7.12 : Peripher und zentral wirkende Muskelrelaxanzien: Ein Vergleich

Skeletal Muscle Relaxants

2.9K Ansichten

article

7.13 : Zentral wirkende Muskelrelaxanzien: Therapeutische Anwendungen

Skeletal Muscle Relaxants

558 Ansichten

JoVE Logo

Datenschutz

Nutzungsbedingungen

Richtlinien

Forschung

Lehre

ÜBER JoVE

Copyright © 2025 MyJoVE Corporation. Alle Rechte vorbehalten